Arrhythmogenic cardiomyopathy

Domenico Corrado, Cristina Basso, Daniel P. Judge

Research output: Contribution to journalArticle

Abstract

Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athletes. Pathological features include loss of myocytes and fibrofatty replacement of right ventricular myocardium; biventricular involvement is often observed. It is a cell-to-cell junction cardiomyopathy, typically caused by genetically determined abnormalities of cardiac desmosomes, which leads to detachment of myocytes and alteration of intracellular signal transduction. The diagnosis of arrhythmogenic cardiomyopathy does not rely on a single gold standard test but is achieved using a scoring system, which encompasses familial and genetic factors, ECG abnormalities, arrhythmias, and structural/functional ventricular alterations. The main goal of treatment is the prevention of sudden cardiac death. Implantable cardioverter defibrillator is the only proven lifesaving therapy; however, it is associated with significant morbidity because of device-related complications and inappropriate implantable cardioverter defibrillator interventions. Selection of patients who are the best candidates for implantable cardioverter defibrillator implantation is one of the most challenging issues in the clinical management.

Original languageEnglish (US)
Pages (from-to)785-802
Number of pages18
JournalCirculation Research
Volume121
Issue number7
DOIs
StatePublished - Sep 1 2017

Fingerprint

Implantable Defibrillators
Cardiomyopathies
Sudden Cardiac Death
Muscle Cells
Myocardium
Desmosomes
Intercellular Junctions
Muscular Diseases
Athletes
Patient Selection
Cardiac Arrhythmias
Signal Transduction
Electrocardiography
Morbidity
Equipment and Supplies
Therapeutics

Keywords

  • Arrhythmias
  • Arrhythmogenic right ventricular cardiomyopathy
  • Cardiac
  • Cardiomyopathies
  • Defibrillators
  • Desmosomes
  • Implantable

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Corrado, D., Basso, C., & Judge, D. P. (2017). Arrhythmogenic cardiomyopathy. Circulation Research, 121(7), 785-802. https://doi.org/10.1161/CIRCRESAHA.117.309345

Arrhythmogenic cardiomyopathy. / Corrado, Domenico; Basso, Cristina; Judge, Daniel P.

In: Circulation Research, Vol. 121, No. 7, 01.09.2017, p. 785-802.

Research output: Contribution to journalArticle

Corrado, D, Basso, C & Judge, DP 2017, 'Arrhythmogenic cardiomyopathy', Circulation Research, vol. 121, no. 7, pp. 785-802. https://doi.org/10.1161/CIRCRESAHA.117.309345
Corrado, Domenico ; Basso, Cristina ; Judge, Daniel P. / Arrhythmogenic cardiomyopathy. In: Circulation Research. 2017 ; Vol. 121, No. 7. pp. 785-802.
@article{59289f3808574ca595fcaf2ab59ef0e0,
title = "Arrhythmogenic cardiomyopathy",
abstract = "Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athletes. Pathological features include loss of myocytes and fibrofatty replacement of right ventricular myocardium; biventricular involvement is often observed. It is a cell-to-cell junction cardiomyopathy, typically caused by genetically determined abnormalities of cardiac desmosomes, which leads to detachment of myocytes and alteration of intracellular signal transduction. The diagnosis of arrhythmogenic cardiomyopathy does not rely on a single gold standard test but is achieved using a scoring system, which encompasses familial and genetic factors, ECG abnormalities, arrhythmias, and structural/functional ventricular alterations. The main goal of treatment is the prevention of sudden cardiac death. Implantable cardioverter defibrillator is the only proven lifesaving therapy; however, it is associated with significant morbidity because of device-related complications and inappropriate implantable cardioverter defibrillator interventions. Selection of patients who are the best candidates for implantable cardioverter defibrillator implantation is one of the most challenging issues in the clinical management.",
keywords = "Arrhythmias, Arrhythmogenic right ventricular cardiomyopathy, Cardiac, Cardiomyopathies, Defibrillators, Desmosomes, Implantable",
author = "Domenico Corrado and Cristina Basso and Judge, {Daniel P.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1161/CIRCRESAHA.117.309345",
language = "English (US)",
volume = "121",
pages = "785--802",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Arrhythmogenic cardiomyopathy

AU - Corrado, Domenico

AU - Basso, Cristina

AU - Judge, Daniel P.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athletes. Pathological features include loss of myocytes and fibrofatty replacement of right ventricular myocardium; biventricular involvement is often observed. It is a cell-to-cell junction cardiomyopathy, typically caused by genetically determined abnormalities of cardiac desmosomes, which leads to detachment of myocytes and alteration of intracellular signal transduction. The diagnosis of arrhythmogenic cardiomyopathy does not rely on a single gold standard test but is achieved using a scoring system, which encompasses familial and genetic factors, ECG abnormalities, arrhythmias, and structural/functional ventricular alterations. The main goal of treatment is the prevention of sudden cardiac death. Implantable cardioverter defibrillator is the only proven lifesaving therapy; however, it is associated with significant morbidity because of device-related complications and inappropriate implantable cardioverter defibrillator interventions. Selection of patients who are the best candidates for implantable cardioverter defibrillator implantation is one of the most challenging issues in the clinical management.

AB - Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athletes. Pathological features include loss of myocytes and fibrofatty replacement of right ventricular myocardium; biventricular involvement is often observed. It is a cell-to-cell junction cardiomyopathy, typically caused by genetically determined abnormalities of cardiac desmosomes, which leads to detachment of myocytes and alteration of intracellular signal transduction. The diagnosis of arrhythmogenic cardiomyopathy does not rely on a single gold standard test but is achieved using a scoring system, which encompasses familial and genetic factors, ECG abnormalities, arrhythmias, and structural/functional ventricular alterations. The main goal of treatment is the prevention of sudden cardiac death. Implantable cardioverter defibrillator is the only proven lifesaving therapy; however, it is associated with significant morbidity because of device-related complications and inappropriate implantable cardioverter defibrillator interventions. Selection of patients who are the best candidates for implantable cardioverter defibrillator implantation is one of the most challenging issues in the clinical management.

KW - Arrhythmias

KW - Arrhythmogenic right ventricular cardiomyopathy

KW - Cardiac

KW - Cardiomyopathies

KW - Defibrillators

KW - Desmosomes

KW - Implantable

UR - http://www.scopus.com/inward/record.url?scp=85030612566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030612566&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.117.309345

DO - 10.1161/CIRCRESAHA.117.309345

M3 - Article

C2 - 28912183

AN - SCOPUS:85030612566

VL - 121

SP - 785

EP - 802

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 7

ER -